Missoula, MT, October 10, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at BioJapan (https://jcd-expo.jp/en/).
New immunotherapy drugs and vaccine technologies have shown great promise in the treatment of allergy, cancer, and autoimmunity. Inimmune is focused on advancing a unique pipeline vaccine adjuvants and immunotherapy treatment options to enhance patient health.
“Inimmune has made great progress towards the advancement of novel immunotherapies in areas of critical importance to global health,” said Alan Joslyn, CEO of Inimmune. “We are excited to have Dr. Evans represent Inimmune at BioJapan and provide an update on the groundbreaking and innovative research being conducted at Inimmune.”
Inimmune will have a booth in the Montana Pavillion (Booth D-55) during BioJapan at PACIFICO Yokohama from October 11-13, 2023.
About Inimmune Corporation
Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, vaccine adjuvants, and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity, and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.
For more information on Inimmune’s research and development of novel vaccine adjuvants and delivery systems, please visit www.inimmune.com.